Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,887.41 -774.32 (-1.20%) CMC Crypto 200
1,333.98 -62.55 (-4.48%)
EQT AB (publ) (EQBBF)
| Previous close | 28.00 |
| Open | 28.00 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 28.00 - 28.00 |
| 52-week range | 18.97 - 35.57 |
| Volume | |
| Avg. volume | 181 |
| Market cap | 33.165B |
| Beta (5Y monthly) | 1.21 |
| PE ratio (TTM) | 233.33 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.33 (0.94%) |
| Ex-dividend date | 28 May 2024 |
| 1y target est | N/A |
- Reuters
UPDATE 2-Skin care company Galderma announces price range for $2.6 bln flotation
Skincare company Galderma was on course to raise 2.3 billion ($2.6 billion) Swiss francs from its upcoming initial public (IPO) offering after a positive response from potential investors. The company, whose products includes Cetaphil, a product for damaged and sensitive skin, as well as fillers and skin creams, early on Wednesday announced a price range of 49 to 53 Swiss francs for its flotation - likely to be one of the biggest in Europe this year. The offering consists of up to 40.5 million new shares and 277,000 existing shares, the company said.
- Reuters SG
UPDATE 5-Skin care company Galderma seeks $2.3 bln in Swiss IPO
Skin care company Galderma plans to raise about $2.3 billion in a flotation on the Swiss stock exchange later this month, it said on Wednesday, in what could be one of the biggest initial public offerings (IPO) in Europe this year. The Swiss company, originally set up as a joint venture between Nestle and L'Oreal, sells Cetaphil, a product for damaged and sensitive skin, as well as muscle relaxants, fillers and creams to treat medical problems for conditions like rosacea.
